Taro Pharma, Sun Pharma’s U.S. Unit, Sees Revenue Improve But Outlook Remains Cautious
Sun Pharma headquarters in Mumbai. (Photographer: Kanishka Sonthalia/Bloomberg)

Taro Pharma, Sun Pharma’s U.S. Unit, Sees Revenue Improve But Outlook Remains Cautious

Sun Pharmaceutical Industries Ltd.’s U.S. subsidiary witnessed a rise in revenue over the preceding quarter, a period when the Covid-19 pandemic hurt sales of its key dermatology segment and as it ...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.